Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

NCT07151586 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Neoplasms
Neoplasm Metastasis
HER 2 Low-expressing Breast Cancer

Interventions

DRUG: Sacituzumab Govitecan / Trastuzumab Deruxtecan

Sponsor

UNICANCER